✦ LIBER ✦

Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

✍ Scribed by Kontani, Keiichi; Kuroda, Noriyuki; Hashimoto, Shin-ichiro; Murazawa, Chisa; Norimura, Shoko; Tanaka, Hiroaki; Ohtani, Masahiro; Fujiwara-Honjo, Naomi; Kushida, Yoshio; Date, Manabu; Haba, Reiji; Houchi, Hitoshi; Yamauchi, Akira; Yokomise, Hiroyasu

Book ID: 120239991
Publisher: Landes Bioscience
Year: 2013
Tongue: English
Weight: 966 KB
Volume: 14
Category: Article
ISSN: 1538-4047
DOI: 10.4161/cbt.22626

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1141 Clinical Use of HER2 Extracellular

1141 Clinical Use of HER2 Extracellular Domain as a Marker to Monitor Cancer Status and Predict the Response to Anti-cancer Treatment in Breast Cancer

✍ Kontani, K.; Hashimoto, S.; Murazawa, C.; Ohtani, M.; Date, M.; Yamauchi, A.; Yo 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Lapatinib: A small-molecule inhibitor of

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

✍ Amye J. Tevaarwerk; Jill M. Kolesar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Prognostic impact of human epidermal gro

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

✍ Jason A Zell, Walter Y Tsang, Thomas H Taylor, Rita S Mehta… 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 202 KB

Impact of hormone receptor status on pat

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

✍ Ines Vaz-Luis, Rebecca A Ottesen, Melissa E Hughes, P Kelly Marcom, Beverly Moy, 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 377 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB